A sequencing panel comprising the six more frequently mutated epigenetic regulators was used to characterize a hematological malignancies cohort, showing no association between mutations in TET2, ASXL1, IDH1/2 or EZH2 and miR-10a/HOXB4 levels. This evidence concerns the gene TET2 and hematologic disorder.